Tag: EXAD

Blue Horseshoe Stocks: IDXG Update & More

Interpace Diagnostics Group, Inc. IDXG

We tracked IDXG last week over a couple of stellar sessions that led to a swing of more than 400%, cautioning that a dip-and-rip could be in the cards after seeing such a volatile move to the upside.

That’s exactly what we’ve seen in the past couple of days, as IDXG came down to find support at the .865 level, and in the ensuing three sessions it’s been steadily registering higher highs and higher lows, getting back to 1.25 yesterday (+45%).

We’ll continue to follow this story, which kicked off with the revelation that Aetna would cover Interpace’s ThyraMir™ test for its 46 million insured members. (>>View PR)

Experience Art & Design, Inc. EXAD

We had EXAD tagged in yesterday’s premarket report and this subpenny play produced a moderate run to kick off the session, even as the larger markets were struggling with the Fed rate hike announcement.

From an early low of .0023, the stock took just the first hour of trading to find its way up to a high of .0038, for a 65% pop. IDXG hung around that level until around lunchtime, and it did come back down to its daily low toward the close, so we’ll be looking for the possibility of a rebound.

Catalyst Biosciences, Inc. CBIO

We’re also interested in following the activity of CBIO today, which is gapping up in the premarket to the tune of more than 100% and looks like it could be lining up to have a big day. We’ll want to make sure it holds above its 50DMA (.80) on any pullbacks, but if it can breach past its 200DMA of 1.31, things could get very interesting.

News broke yesterday via an 8-K filing that CBIO had entered into a definitive agreement with Wyeth LLC, (wholly-owned subsidiary of Pfizer Inc.) to transfer exclusive rights to research, develop, manufacture and commercialize Factor VIIa variants, CB 813a and CB 813d, as well as transferring the investigational NDA to CBIO as well. (>>View Filing)


Fresh Options Idea:  Transocean, Inc. RIG $15 and $14.50 Puts

Extended Watchlist:
VCEL, NWBO, BCLI, BPMX, DLOV, PPMT

Blue Horseshoe Stocks: QFOR, NDEV Updates & More


Quadrant 4 Systems Corp. QFOR

Yesterday marked the first time we ever mentioned QFOR in any of our premarket reports, and in a stroke of fantastic timing, the stock made one heck of a debut for us.

We were interested because we noticed that after taking a huge beating from nearly .20 at the beginning of the month, the stock finally started to show some signs of life, trending off of its lows on Monday.

That momentum helped facilitate yesterday’s run from a low of .04175 to .0712, which worked out to a healthy intraday pop of 80% on more than twice the monthly average volume. We want to continue to monitor this as a recovery play, as the regaining of even a portion of the ground that it lost in recent weeks would represent significant gains from the present juncture.

Cellectar Biosciences, Inc. CLRB

Speaking of bottom plays, there’s another one hitting our scanners this morning in CLRB. This stock found new 6-month lows yesterday, and from a technical standpoint, this is what can only be referred to as an incredibly ripe chart.

We’ve included a snapshot below, and as you can see, it currently boasts many of the  characteristics that we constantly watch for, and often benefit from. Trading at recent relative lows, with an RSI indicating oversold, the MACD converging toward an impending bullish cross, and a sizable gap to the upside.

It’s for these reasons that CLRB must be afforded a spot on our watch-screens as we cruise through midweek.

Novus Acquisition & Development Corp. NDEV

After tagging NDEV in Monday’s morning report and witnessing a nice initial move from .30-.442 (+47%), we followed up yesterday and cautioned that a continuation of momentum made it necessary to stay on its trail, and we’re glad we did.

The stock produced a second straight solid session for us, running from its morning low of .43 to a new high of .559, a intraday pop of 30% and a two-day increase amounting to 86% High volume to the tune of more than five times its monthly average, and another strong close will keep NDEV’s slot on our radar safe for the time being.

Extended Watchlist:
ACAU, DTEA, ECTE, EXAD, PGUS, PLX(Bottom-Bouncer)

Blue Horseshoe Stocks: EXAD Review, Options & More

Experience Art & Design, Inc. EXAD – Impressive Run Continues

Yesterday morning, we were just updating readers on the call we made last Monday on EXAD at a low of .0009. It had subsequently run up to a high of .0024 (+167%) and we were congratulating folks who latched on for a nice profit.

We went on to mention that the stock was “exhibiting momentum-play characteristics” and that we’d continue to be interested if it could maintain support above .0015 on any pullbacks. Ultimately, there was no pullback. EXAD opened at Friday’s high and closing price of .0024, and took off on another bullish session that took it to an impressive new high of .0039; an intraday pop of 62%.

It closed at its high for the second straight session, and pushed our overall observed range in just a week’s time to 333%  As long as the stock continues to register higher base levels of support, we’ll remain interested in what has concisely demonstrated itself to be an extreme momentum-mover!

Shire plc SHPG – Options Idea

We also want to follow up on our options trading idea that we floated in yesterday’s premarket report, the SHPG Weekly $175-180 Calls. We said that we’d have them on watch throughout the course of the week, and would just like to reiterate that this morning.

We’re seeing a notable gap-up in early trading to day that should begin to fuel healthy observed gains for our highlighted contracts.


ChromaDex Corp CDXC

We have an interesting little story that has unfolded for CDXC inside of the past 24 hours. Yesterday a report and “Shareholder Alert” was published that effected a steep decline which you can very plainly see on the included chart.

Frank L. Jaksch, CEO of ChromaDex immediately responded, alleging that “The report appears to be a blatant and transparent attempt by a shortseller or shortsellers to profit from an immediate and precipitous decline in the company’s share price through the use of an opinion piece published anonymously and laden with misinformation…”

Even if the report contained elements of truth, the sharp selloff which occurred yesterday seems to be an over-reaction. We’ll have CDXC on recovery watch in coming sessions.

Extended Watchlist:
ELED, BHGI, RVUE, FTEK,
CUR(Gap to fill to .55)